HCW Biologics
HCWB
12 hedge funds and large institutions have $1.48M invested in HCW Biologics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
73% more capital invested
Capital invested by funds: $855K → $1.48M (+$621K)
9% more funds holding
Funds holding: 11 → 12 (+1)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$456K |
| 2 |
BlackRock
New York
|
+$50.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$24K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$22.4K |
| 5 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$164K |
| 2 |
Renaissance Technologies
New York
|
-$28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HighTower Advisors
Chicago,
Illinois
| $588K | +$456K | +856 | +2,038% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $225K | – | – | – |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $155K | +$22.4K | +42 | +22% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $145K | +$24K | +45 | +25% |
|
|
5
Two Sigma Investments
New York
| $140K | -$164K | -307 | -59% |
|
|
6
BlackRock
New York
| $108K | +$50.7K | +95 | +136% |
|
7
State Street
Boston,
Massachusetts
| $56K | +$1.07K | +2 | +2% |
|
|
CAM
8
Cresset Asset Management
Chicago,
Illinois
| $48K | +$11.2K | +21 | +40% |
|
9
UBS Group
Zurich,
Switzerland
| $5K | +$3.73K | +7 | New |
|
|
FWM
10
Focused Wealth Management
Newburgh,
New York
| $3K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $2K | +$1.6K | +3 | New |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
|
13
Renaissance Technologies
New York
| – | -$28K | -50 | Closed |
|
HCWB Hedge Fund Activity: Q1 2022 in Review
12 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q1 2022, worth a combined $1.48M — up 73% from $855K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HCWB positions and 1 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $456K. The largest seller was Two Sigma Investments, cutting an estimated $164K.
- 12 institutional investors held HCW Biologics (HCWB) as of Q1 2022, up from 11 in Q4 2021.
- Funds reported $1.48M of HCW Biologics stock for Q1 2022, up 73% quarter-over-quarter.
- 2 funds opened new HCW Biologics positions in Q1 2022 and 1 closed out, a net change of +1 holder.
- The largest HCW Biologics buyer in Q1 2022 was HighTower Advisors, an estimated $456K added.
- The largest HCW Biologics seller in Q1 2022 was Two Sigma Investments, an estimated $164K sold.
Based on aggregated 13F filings for Q1 2022.